Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Citi lifts Currys price target, reiterates 'buy' rating

(Sharecast News) - Citi reiterated its 'buy' rating on Currys on Tuesday and lifted the price target to 150p from 121p, saying that iD Mobile and buybacks are set to provide material upside. The bank said that following around £50m working capital investments made in the last two years towards growing iD mobile, its proprietary cohort analysis suggests the benefits from the investment will become apparent in the near term.

Citi estimates that iD mobile will account for the majority of the circa 2% per annum growth in UK & Ireland like-for-like sales it forecasts for FY26e-28e, "implying market conditions need not be favourable to sustain revenue expectations".

"We estimate that 30-45% of UK&I EBIT will come from iD mobile FY26e/FY27e/FY28e (versus circa 20% in FY25a), as the headwinds from ramp-up of newer cohorts fade," Citi said. "We believe iD Mobile alone is worth circa £600m or 45% of Currys' current market cap."

Citi also said it models £50m/£20m/£35m of buybacks in FY26e/FY27e/FY28e, driving a cumulative earnings per share uplift of 1%/5%/7% in addition to the circa 2%-3% dividend yield.

The bank sees further upside in the shares despite a strong year-to-date performance.

At 1010 BST, the shares were up 1% at 120.30p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.